November 13, Company Update Deutsches Eigenkapitalforum 2012
|
|
- Dulcie Waters
- 6 years ago
- Views:
Transcription
1 November 13, 2012 Company Update Deutsches Eigenkapitalforum 2012
2 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company s Annual Report. 2
3 Components of the Business Innovative Product Pipeline MOR103 shows excellent safety and efficacy in RA Partner Phase 2 read-outs coming Technology-driven Alliances Proven HuCAL platform Ylanthia launched 21 clinical programs AbD Serotec Financially Strong Emerging diagnostics business Research antibody catalog Sustainably cash-flow positive Strong balance sheet 3
4 Pipeline Gathering Momentum MOR103 MOR208 Excellent clinical proof-of-concept and safety data generated in rheumatoid arthritis Phase 1b/2a trial Positive safety and efficacy data from Phase 1/2a trial in CLL/SLL Gantenerumab CNTO1959 Advanced to Phase 3 development for Alzheimer s Disease by Hoffmann La Roche Solanezumab results provide support for Roche trial design Selected by Dominantly-Inherited Alzheimer Network (DIAN) for world-wide trial in early-onset AD Janssen commences Phase 2 RA comparison study with Stelara BYM338 OMP-59R5 Novartis completes Phase 2 study in sporadic inclusion body myositis Oncomed commences Phase 1b/2 trial in first-line advanced pancreatic cancer 4
5 Innovative Product Pipeline 5
6 76 Therapeutic Antibody Programs 21 Programs in Clinical Development Program Partner Target Indication Discovery Preclinic Phase 1 Phase 2 Phase 3 Gantenerumab Roche Amyloid-ß Alzheimer s Disease MOR103 (2 programs) - GM-CSF CNTO888 Janssen/J&J MCP-1 (CCL-2) IPF CNTO1959 (2 programs) Janssen/J&J IL23p19 Rheumatoid Arthritis Multiple sclerosis Psoriasis RA BHQ880 Novartis DKK-1 Cancer BYM338 Novartis - Musculoskeletal NOV 3 Novartis - not discl. NOV 4 Novartis - Ophthalmology OMP-59R5 OncoMed/GSK Notch 2 Cancer MOR208 - CD19 CLL MOR202 - CD38 MM BAY Bayer Healthcare Mesothelin (ADC) Cancer BI 1 BI - not discl. CNTO3157 Janssen/J&J - Asthma CNTO 5 Janssen/J&J - Inflammation NOV 5 Novartis - Inflammation NOV 6 Novartis - Cancer OMP-18R5 OncoMed/Bayer Fzd 7 Cancer PFE 1 Pfizer - Cancer 21 Programs Various Partners - Various Indications 34 Programs Various Partners - Various Indications 70 Partnered Programs 6 Proprietary Programs 6
7 MOR103 A Novel Anti-Inflammatory Antibody Large Market and Unmet Need in Rheumatoid Arthritis Approved biologics, mostly anti-tnf therapies, generate $20bn in annual sales 30-40% of patients do not adequately respond to anti-tnfs 50% of responders stop responding within 2 years MOR103 Ultra-high affinity HuCAL IgG1 targeting GM-CSF Potential for superior efficacy and better safety than current treatments Intellectual Property Exclusive license to a US patent covering anti-gm-csf antibodies for the treatment of chronic inflammatory conditions US patent on MOR103 composition of matter 7
8 MOR103 Phase 1b/2a Trial in Rheumatoid Arthritis Trial design 96 patients with active, mild-to-moderate RA (DAS28 5.1) Randomized, double-blind, placebo-controlled Dose regimen: 0.3, 1.0 and 1.5 mg/kg weekly x 4 injected intravenously vs. placebo 26 sites in Holland, Germany, Poland, Bulgaria & Ukraine Primary outcome measures Adverse event rate and safety profile Secondary outcome measures DAS28, ACR core set measures and EULAR28 response criteria, MRI (synovitis & bone edema), patient reported outcomes at 4 and 8 weeks 8
9 % of patients MOR103 Shows Impressive Efficacy & Fast Onset of Action ACR20 Response at week 4 (FAS population) p< Placebo MOR mg MOR mg MOR mg ACR20 ranks amongst highest observed for a biologic in RA after 4 weeks 50 Very fast onset of therapeutic effect within 2 weeks Robust and durable responses 10 weeks beyond treatment Imaging confirms anti-inflammatory activity Week 4 FAS: Full Analysis Set, N= 96 9
10 % of patients ACR20 Scores Compare Favorably to Other Biological DMARDs ACR20 Response over 4 weeks* Placebo MOR103 1 mg/kg MOR mg/kg mavrilimumab adalimumab abatacept tocilizumab in TNF-IR Time (weeks) Level of efficacy and speed of onset exceed those seen for mavrilimumab, adalimumab (Humira), abatacept (Orencia) and tocilizumab (Actemra) * Data from separate clinical studies 10
11 MOR103 Safe & Well-tolerated at All Doses Serious Adverse Events (SAEs) No treatment-related SAEs in the active treatment groups Related adverse events (AEs) More frequent in placebo group (25.9%) than in active treatment group (14.5%) Most common AEs ( 6%) were nasopharyngitis, RA flare, fatigue and hypertension Majority of AEs were of mild intensity One patient on placebo discontinued treatment due to an AE 11
12 MOR103 Looking Ahead Rheumatoid arthritis Expect even higher efficacy on longer treatment development in moderate to severe patients Potential for dosing monthly or even less frequently Multiple sclerosis Phase 1b study in MS patients ongoing GM-CSF is the only non-redundant inflammatory cytokine in EAE Major unmet need in progressive forms of the disease Sub-cutaneous formulation Phase 1 study in healthy volunteers confirms feasibility of subcutaneous administration Partnering Discussions ongoing 12
13 MOR208 (XmAb5574) A Novel Anti-Cancer Antibody Large Market and Unmet Need High unmet medical need in NHL, CLL & ALL Revenues with approved drugs for B cell malignancies exceed $5bn Relapsing patients have limited treatment options Phase 2 data for blinatumomab validate CD19 as target for B-cell malignancies MOR208 Humanized, high affinity anti-cd19 antibody Exclusive license from Xencor Antibody comprises a proprietary Xencor modification of the Fc part of the antibody leading to rapid and sustained B-cell depletion 13
14 MOR208 Has Compelling Prospects MOR208 Has An Attractive Competitive Profile Expect convenient dosing schedule Straightforward manufacturing Potential for good safety profile Significantly increased ADCC compared to unmodified antibody Clinical Development Preclinical data show synergistic effects on target cell killing in combination therapies with existing drugs Phase 1, in relapsed or refractory CLL/SLL patients, to be presented at ASH 2012: Favorable safety profile 3/27 partial responses and 22/27 patients with stable disease Results from trial extension expected in Q Phase 2: Trials in B cell malignancies starting Q
15 MOR202 A Novel Antibody for Multiple Myeloma Large Market and Unmet Need Revenues with approved drugs in MM exceed $2bn, but median survival is only 3-5 years MOR202 High affinity HuCAL antibody targeting CD38 Competitive Profile Preclinical data show strong synergy in combinations of MOR202 with Velcade or Revlimid New pre-clinical data to be presented at ASH Clinical Development Phase 1, in relapsed or refractory MM patients ongoing Phase 2a, monotherapy extension Phase 1b, MOR202 + Velcade Phase 1b, MOR202 + Revlimid Up to 82 patients, at sites in Germany and Austria 15
16 Gantenerumab: A HuCAL Antibody Being Developed by Roche for Alzheimer s Disease Large Market and Unmet Need Alzheimer s disease is estimated to affect 25 million people worldwide Increasing with aging population Once symptoms for AD dementia have appeared, it may be too late to treat Picture: Courtesy of Roche 16
17 % Amyloid change from baseline Gantenerumab is the Most Advanced Antibody in Prodromal AD Patients Gantenerumab High affinity HuCAL antibody targeting amyloid-β Binds & breaks down amyloid-β fibrils and plaques Clinical Development Phase 1, in patients completed Gantenerumab reduces brain amyloid 3x faster than other amyloid-targeting substances Potentially pivotal Phase 3 study ongoing 770 prodromal patients, 2 doses, placebocontrolled 104 weeks on drug CDR-SOB, ADAS-COG, change in brain amyloid Initial data expected in 2015: favorable outcome could support a marketing application Data from Phase 1 Effect of gantenerumab on amyloid load as indexed by PET SUVR at end of treatment 17
18 Technology-driven Alliances 18
19 Proprietary Technology Platform Underpins Lucrative Alliances MorphoSys has successfully partnered its human antibody technology HuCAL with many of the leading pharmaceutical companies Lucrative model Makes MOR cash-flow positive Funds proprietary R&D Future upside from milestones & royalties Target MorphoSys Pharma partner HuCAL antibody drug candidate R&D funding Technology licence fees Milestones and royalties 19
20 Commercial Launch of Ylanthia Slonomics Best technology for protein libraries secured in Sloning acquisition Deals have already paid for acquisition Pfizer, Novozymes, unnamed pharma Ylanthia Totally new antibody platform Higher quality antibodies, greater diversity faster lead generation Opens new opportunities New technologies now part of expanded Novartis strategic alliance Novartis committed through 2017 with annual license fees, FTE funding, milestones, royalties MOR free to partner platform broadly 20
21 AbD Serotec 21
22 AbD Serotec Segment Complements Therapeutic Business Research Activities HuCAL Diagnostic Applications Catalogue of 15,000+ products Stable and recurring cash flows Customers comprise universities, government bodies, life science companies Website, ecommerce Custom antibody generation Using proprietary technologies to deliver superior Dx antibodies Future upside via royalties Working with over 20 Dx companies 22
23 Strong Financials 23
24 Key Financials in million 2011 Guidance 2012* 9M 2012 Group Revenues Total Operating Expenses COGS Funded R&D Proprietary R&D (incl. technology development) Sales, General & Administrative Expenses EBIT (2.3) Cash & Marketable Securities and Interest-bearing Assignable Loans (at end of period) * as of Nov 7,
25 Shareholdings Shares issued: 23,308,622 (September 30, 2012) Treasury stock: 255,415 (September 30, 2012) 25
26 Forthcoming Pipeline Developments Proprietary Portfolio MOR103 phase 1b/2a data at ACR 2012 (November) MOR208 phase 1 data at ASH 2012 (December) MOR208 data from extended dose group (Q1 2013) MOR202 interim data from phase 1 open label study Partnered Pipeline Several Phase 2 studies to complete shortly BHQ880 (Novartis, oncology to be presented at ASH) CNTO888 (Janssen Biotech, IPF) BYM338 (Novartis, musculoskeletal diseases) NOV-3 (n.d.) NOV-4 (ophthalmology) Roche hints at interim analysis of gantenerumab Phase 3 study during 2013 * MorphoSys estimates based on publicly-available information 26
27 Thank You Jens Holstein Chief Financial Officer Phone +49 (0)89 / Fax +49 (0)89 / Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Phone +49 (0)89 / Fax +49 (0)89 / investors@morphosys.com HuCAL, HuCAL GOLD, HuCAL PLATINUM, CysDisplay, RapMAT, aryla, Ylanthia and 100 billion high potentials are registered trademarks of MorphoSys AG. Slonomics is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
Q Results Conference Call
August 2, 2018 Q2 2018 Results Conference Call MorphoSys AG Today on the Call Dr. Simon Moroney Jens Holstein Chief Executive Officer Chief Financial Officer 2 This presentation includes forward-looking
More informationResults FY2017 & Outlook 2018
March 13, 2018 Results FY2017 & Outlook 2018 MorphoSys AG Today on the Call Dr. Simon Moroney Jens Holstein Dr. Malte Peters Chief Executive Officer Chief Financial Officer Chief Development Officer 2
More informationMorphoSys. Company Update. Jefferies 2016 Healthcare Conference June 7 10, 2016
MorphoSys Company Update Jefferies 2016 Healthcare Conference June 7 10, 2016 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationJefferies Autumn 2015 Global Healthcare Conference. Company Update November 18, 2015
Jefferies Autumn 2015 Global Healthcare Conference Company Update November 18, 2015 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those
More informationEngineering the Medicines of Tomorrow
January 7-11, 2018 Engineering the Medicines of Tomorrow Company Update This presentation includes forward-looking statements. Actual results could differ materially from those included in the forwardlooking
More informationApril Company Update
April 2015 Company Update MorphoSys - April 2015 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements
More informationGroup Management Report
12 The Company Group Management Report Financial Statements Group Management Report In 2010, MorphoSys showed solid financial performance and was able to increase the value of its proprietary product portfolio
More informationFirst Quarter Interim Statement January March 2017
First Quarter Interim Statement January March 2017 2 Group Interim Statement Contents MorphoSys Group: First Quarter Interim Statement January March 2017 3 SUMMARY 5 GROUP INTERIM STATEMENT 5 OPERATING
More informationEngineering the Medicines of Tomorrow
December 2018 Engineering the Medicines of Tomorrow Company Update This presentation includes forward-looking statements. This communication contains certain forward-looking statements concerning the MorphoSys
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationConference Call L-MIND data
DECEMBER 12, 2017 Conference Call L-MIND data MorphoSys AG Today on the Call Dr. Simon Moroney Dr. Malte Peters Jens Holstein Anke Linnartz CEO CDO CFO Head of Corporate Communications & IR MorphoSys AG,
More informationInnovating Antibodies, Improving Lives. 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019
Innovating Antibodies, Improving Lives 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation contains forward looking statements. The words believe,
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationJ.P. Morgan Healthcare Conference. January 15, 2009
J.P. Morgan Healthcare Conference January 15, 2009 Facet Biotech Corporation Forward-looking Statements This presentation contains forward-looking statements involving risks and uncertainties and Facet
More informationADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT
FOR IMMEDIATE RELEASE December 21, 2017 Eisai Co., Ltd. Biogen Inc. ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT CRITERIA FOR SUCCESS AT 12-MONTH ANALYSIS
More informationIntroducing MN-166 Multiple Sclerosis. July 9, 2008
Introducing MN-166 A New Treatment Paradigm for Multiple Sclerosis July 9, 2008 MediciNova, Inc. 2008 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationFourth Quarter and Full Year Financial and Operational Results Conference Call March 21, 2018
Fourth Quarter and Full Year 2017 Financial and Operational Results Conference Call March 21, 2018 Copyright Akari Therapeutics, Plc - 2018 Disclaimers Certain statements in this presentation constitute
More informationFirst Quarter 2018 Financial Results. May 8, 2018
First Quarter 2018 Financial Results May 8, 2018 Agenda Introduction Sarah Carmody, Senior Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer First Quarter
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationOral NT-KO-003 for the Treatment of Multiple Sclerosis
Oral for the Treatment of Multiple Sclerosis Madrid, 27 de noviembre de 2013 Content 1. The Company 2. The Product a) Target Indications b) Innovative mechanisms of action c) Differential features facing
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationRegeneron Reports Third Quarter 2010 Financial Results and Business Highlights
Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights TARRYTOWN, N.Y., Oct 28, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today
More informationPhylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development
Phylogica Harnessing Biodiversity for Peptide Therapies Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development Introduction Biotech company offering leading peptide drug discovery
More informationMarch Company Update
March 2016 Company Update Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various
More informationRoche Committed to Innovation. Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008
Roche Committed to Innovation Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008 This presentation contains certain forward-looking statements. These forward-looking statements
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationEngineering the Medicines of Tomorrow
February 14+15, 2018 Engineering the Medicines of Tomorrow Company Update This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationMomenta Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2, 2017 Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results --Company reports Glatopa 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the
More informationGenentech Contacts: Media: Tara Cooper (650) Investor: Kathee Littrell (650)
NEWS RELEASE Genentech Contacts: Media: Tara Cooper (650) 225-5505 Investor: Kathee Littrell (650) 225-1034 XOMA Media/Investor Contacts: Laura Zobkiw (510) 204-7273 Peter Davis (510) 204-7231 FDA APPROVES
More informationGenmab an antibody innovation powerhouse. Jan van de Winkel
Genmab an antibody innovation powerhouse Jan van de Winkel Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar
More informationi-bodies a new class of protein therapeutics to treat human disease
i-bodies a new class of protein therapeutics to treat human disease AGM November 2016 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is
More informationEngineering the Medicines of Tomorrow
June 2018 Engineering the Medicines of Tomorrow Company Update This presentation includes forward-looking statements. This communication contains certain forward-looking statements concerning the MorphoSys
More informationSustainable Profitable Growth through Innovation. Pascal Soriot Chief Operating Officer Roche Pharmaceuticals
1 Sustainable Profitable Growth through Innovation Pascal Soriot Chief Operating Officer Roche Pharmaceuticals 2 Q1 2009: A good start into the year 3 Q1 2010: High growth for both divisions Well above
More informationEngineering the Medicines of Tomorrow
January 15, 2018 Engineering the Medicines of Tomorrow Company Update This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationQuarter End Results. Period Ended September 30, 2018
Quarter End Results Period Ended September 30, 2018 Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions
More informationImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision
More informationOpexa Therapeutics, Inc.
Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationAntibody therapeutic approaches for cancer
Antibody therapeutic approaches for cancer Date2innovate Utrecht, March 21, 2014 Jan van de Winkel Forward Looking Statement This presentation contains forward looking statements. The words believe, expect,
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationCompany Update. April 2009
Company Update April 2009 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various
More informationABLYNX ANNOUNCES Q BUSINESS UPDATE
REGULATED INFORMATION ABLYNX ANNOUNCES Q1 2014 BUSINESS UPDATE GHENT, Belgium, 14 May 2014 - Ablynx [Euronext Brussels: ABLX] today announced its non-audited business update, summarising Ablynx s financial
More informationDeborah Dunsire, M.D. President and CEO. Annual Meeting of Shareholders Cambridge, MA May 4, 2006
Deborah Dunsire, M.D. President and CEO Annual Meeting of Shareholders Cambridge, MA May 4, 2006 2006 Millennium 2006 Pharmaceuticals Millennium Inc. Pharmaceuticals, Inc. Agenda 2005 Key Accomplishments
More informationINVESTOR PRESENTATION FULL YEAR 2007 RESULTS. February 2008
INVESTOR PRESENTATION FULL YEAR 2007 RESULTS February 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may, would,
More information2006 Half Year Financial Results. July 27, 2006
2006 Half Year Financial Results July 27, 2006 Agenda Introduction Roch Doliveux CNS Allergy Inflammation R&D Day H1 2006 Financial Results Luc Missorten FY 2006 Outlook Conclusion Roch Doliveux A Global
More information14 May Evotec Q1 2013: Driving Innovation Efficiency
14 May 2013 Evotec Q1 2013: Driving Innovation Efficiency STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION EFFICIENCY EVOTEC S DRUG DISCOVERY PLATFORM GENERATES GROWTH NEW HORMONE IDENTIFIED
More information12-Month Interim Analysis of APOE4 Carriers for Fixed and Titration Dosing Regimens in PRIME, a Phase 1b study of Aducanumab
12-Month Interim Analysis of APOE4 Carriers for Fixed and Titration Dosing Regimens in PRIME, a Phase 1b study of Aducanumab Vissia Viglietta, 1 John O Gorman, 1 Leslie Williams, 1 Tianle Chen, 1 Ahmed
More informationAffimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
FOR IMMEDIATE RELEASE Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated;
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationAVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter
More informationBio Latin America Conference October 15, 2015
Bio Latin America Conference October 15, 2015 About RuiYi and BioReal RuiYi, Inc. La Jolla, CA Innovative antibodies with upsized development potential BioReal Brazil (wholly owned subsidiary of RuiYi)
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationQuarter End Results. Period Ended June 30, 2018
Quarter End Results Period Ended June 30, 2018 Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions
More informationAdvancing the Frontiers of mab mixtures
Advancing the Frontiers of mab mixtures...unlocking the power of the immune system Symphogen Corporate Presentation June 216 Symphogen/1 Symphogen Overview Privately held company - 125 employees Headquarters
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION March 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may, would, could and plan and similar
More informationBioArctic. Gunilla Osswald, PhD, CEO December 4, 2017 Lars Lannfelt, Professor, MD, Senior Advisor and Co-Founder
BioArctic Gunilla Osswald, PhD, CEO December 4, 2017 Lars Lannfelt, Professor, MD, Senior Advisor and Co-Founder Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic
More informationFourth Quarter and Full Year 2017 Financial Results. February 21, 2018
Fourth Quarter and Full Year 2017 Financial Results February 21, 2018 Agenda Introduction Sarah Carmody, Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer
More informationRoche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis
Investor Update Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis Data presentations will
More informationSosei Business Update and Revised Financial Forecast Following Acquisition of Arakis
Sosei Business Update and Revised Financial Forecast Following Acquisition of Arakis Tokyo, Japan 16 December 2005: Sosei Co. Ltd ("Sosei" - 4565, Tokyo Stock Exchange MOTHERS index), a leading Japanese
More informationAgios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. The people pictured here are some of the many friends and family of Agios employees affected by cancer. All of us at Agios are passionate about transforming patients lives.
More informationLicense Agreement of Tildrakizumab for Psoriasis in Europe
License Agreement of Tildrakizumab for Psoriasis in Europe July 28 th 2016 Disclaimer This document has been prepared by Almirall, S.A. (the Company ) exclusively for use during the presentation. This
More informationEXANE Conference. Jérôme Contamine, Executive Vice President, Chief Financial Officer. Paris June 13, 2017
EXANE Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Paris June 13, 2017 Forward Looking Statements This presentation contains forward-looking statements as defined in the
More informationJ.P. Morgan Health Conference January 10, Kiran Mazumdar-Shaw
J.P. Morgan Health Conference January 10, 2011 Kiran Mazumdar-Shaw 1 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are
More informationMedical breakthroughs have always driven our business
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationBioArctic Gunilla Osswald, CEO December 5, Carnegie Nordic Healthcare Day
BioArctic Gunilla Osswald, CEO December 5, 2017 Carnegie Nordic Healthcare Day Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic ) solely for the benefit of
More informationChanging Lives. Daniel Junius, President and CEO June 3, Nasdaq: IMGN
Changing Lives Daniel Junius, President and CEO June 3, 215 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These
More informationImmune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01,
More information10 November Evotec reports nine months results: Upside materialising
10 November 2011 Evotec reports nine months results: Upside materialising - DISCOVERY ALLIANCE BUSINESS REPORTS PROFITABLE GROWTH WITH REVENUES UP 54% AND A POSITIVE OPERATING RESULT OF 9.5 M - STRONG
More informationNew Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More information90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
Exhibit 19: Key Psoriasis Clinical Trials (Phase 3) Data compiled not from head-to-head studies Exhibit 20: Long-Term Response PASI-90 and PASI-100 (Phase 3) Data compiled not from head-to-head studies.
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Michael Severino Vice Chairman and President January 9, 2019 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation are, or
More informationMarket Analysis & Segmentation. Gary Phillips CEO Bioshares 29 July 2016
Market Analysis & Segmentation Gary Phillips CEO Bioshares 29 July 2016 1 Forward looking statement This document contains forward looking statements, including statements concerning Pharmaxis future financial
More informationRegeneron Reports Second Quarter 2010 Financial and Operating Results
Regeneron Reports Second Quarter 2010 Financial and Operating Results July 28, 2010 TARRYTOWN, N.Y., July 28, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN)
More informationPieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update
March 22, 2016 Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update Company to Host an Investor Conference Call on Wednesday, March 23, 2016 at 10:00 AM ET BOSTON, MA --
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More informationGunilla Osswald, PhD, CEO RedEye CNS Event, October 4, 2018
BioArctic AB Company presentation Gunilla Osswald, PhD, CEO RedEye CNS Event, October 4, 2018 Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic ) solely for
More informationQuarter End Results. Period Ended March 31, 2018
Quarter End Results Period Ended March 31, 2018 Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions
More informationADDING VALUE TO A PRODUCT S LIFE CYCLE MANAGEMENT: Product Enhancement Through Drug Delivery Systems
ADDING VALUE TO A PRODUCT S LIFE CYCLE MANAGEMENT: Product Enhancement Through Drug Delivery Systems Anand Baichwal, Ph.D. Sr. VP of Research & New Technology Development, and Chief Scientific Officer
More informationBioArctic AB Interim Report January - June Gunilla Osswald, CEO Jan Mattsson, CFO August 23, 2018
BioArctic AB Interim Report January - June 2018 Gunilla Osswald, CEO Jan Mattsson, CFO August 23, 2018 Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic ) solely
More informationStrategic Collaboration with Amgen to develop MP0310
Strategic Collaboration with Amgen to develop MP0310 Patrick Amstutz, CEO Webcast of Molecular Partners AG, Switzerland (SIX: MOLN) December 19, 2018 2018 Molecular Partners AG Slide 1 Molecular Partners:
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationNovel targets, better molecules
Novel targets, better molecules Investor Presentation November 2014 Copyright 2014 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for
More informationPresentation to J.P. Morgan 33rd Annual Healthcare Conference. Moshe Manor President and CEO January 15, 2015
Presentation to J.P. Morgan 33rd Annual Healthcare Conference Moshe Manor President and CEO January 15, 2015 1 Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationNuevolution AB (publ) Presentation Q4 2015/16
Nuevolution AB (publ) Presentation Q4 2015/16 FORWARD-LOOKING STATEMENTS Slide 2 Matters discussed in this presentation may constitute forward-looking statements. Forward-looking statements are statements
More informationSynthetic Biologics Reports Year End 2012 Financial Results
April 16, 2013 Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md.,
More informationFirst Quarter 2018 Financial Results & Update
First Quarter 2018 Financial Results & Update April 26, 2018 Forward-Looking Statements and Non-GAAP Financial Information 2 Certain statements set forth in this presentation constitute forward-looking
More informationREDX PHARMA PLC ( Redx or Company or Group ) Interim Results
24 May 2016 AIM: REDX REDX PHARMA PLC ( Redx or Company or Group ) Interim Results Redx (AIM: REDX), the drug discovery and development company, is pleased to announce its unaudited interim results for
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More informationDEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS JEFFERIES GLOBAL HEALTHCARE CONFERENCE JUNE 8, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationTreating and Preventing Infectious Disease. November 2011 Nasdaq: INHX
Treating and Preventing Infectious Disease November 2011 Nasdaq: INHX Safe Harbor This presentation contains forward looking statements about Inhibitex and its business, business prospects, strategy and
More informationLeading the world in novel adult stem cell therapies Half-Year Financial Results
Leading the world in novel adult stem cell therapies 2013 Half-Year Financial Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following
More informationDevelopment of differentiated immuno-oncology therapeutics by using multivalent Nanobodies
Nanobodies Innovative therapeutics Development of differentiated immuno-oncology therapeutics by using multivalent Nanobodies Immune Checkpoint Inhibitors Europe Sandra Li - 17 November 2016 Forward looking
More informationSanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care
Sanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care January 22, 2018 Forward Looking Statements This presentation contains forward-looking statements.
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More information